Publications

Nebie E.I, van Eeuwijk P, Sawadogo H.N, Reus E, Utzinger J, Burri C. Operational differences between product development partnership, pharmaceutical industry, and investigator initiated clinical trials. Trop Med Infect Dis. 2024;9(3):56. DOI: 10.3390/tropicalmed9030056

Blum J, Staehelin C, Neumayr A, Chappuis F, Burri C. Schlafkrankheit: der gefährliche Schlaf nach dem Erfolg. Swiss Med Forum. 2023;23(3):846–848. DOI: 10.4414/smf.2023.09243

Brunner N.C, Karim A, Athieno P, Kimera J, Tumukunde G, Angiro I, Signorell A, Delvento G, Lee T.T, Lambiris M, Ogwal A, Nakiganda J, Mpanga F, Kagwire F, Amutuhaire M, Burri C, Lengeler C, Awor P, Hetzel M.W. Starting at the community: treatment-seeking pathways of children with suspected severe malaria in Uganda. PLOS Glob Public Health. 2023;3(7):e0001949. DOI: 10.1371/journal.pgph.0001949

Burri C, Mäser P, Chappuis F. Human African trypanosomiasis. In: Farrar J,Hotez P.J,Junghanss T,Kang G,Lalloo D,White N.J,Garcia P.J, eds. Manson's Tropical Diseases, 623-635. Amsterdam: Elsevier, 2023. DOI: 10.1016/B978-0-7020-7959-7.00051-8

Hetzel M.W, Awor P, Tshefu A, Omoluabi E, Burri C, Signorell A, Lambiris M.J, Visser T, Cohen J.M, Buj V, Lengeler C. Pre-referral rectal artesunate: no cure for unhealthy systems. Lancet Infect Dis. 2023;23(6):e213-e217. DOI: 10.1016/S1473-3099(22)00762-9

Hetzel M.W, Okitawutshu J, Tshefu A, Omoluabi E, Awor P, Signorell A, Kwiatkowski M, Lambiris M.J, Visser T, Cohen J.M, Buj V, Burri C, Lengeler C. Pre-referral rectal artesunate is no "magic bullet" in weak health systems. BMC Med. 2023;21:119. DOI: 10.1186/s12916-023-02777-y

Kaboré J.M.T, Siribié M, Hien D, Soulama I, Barry N, Baguiya A, Tiono A.B, Burri C, Tchouatieu A.M, Sirima S.B. Feasibility and acceptability of a strategy deploying multiple first-line artemisinin-based combination therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso. Trop Med Infect Dis. 2023;8(4):195. DOI: 10.3390/tropicalmed8040195

Lambiris M.J, Venga G.N, Ssempala R, Balogun V, Galactionova K, Musiitwa M, Kagwire F, Olosunde O, Emedo E, Luketa S, Sangare M, Buj V, Delvento G, Tshefu A, Okitawutshu J, Omoluabi E, Awor P, Signorell A, Hetzel M.W, Lee T.T, Brunner N.C, Cereghetti N, Visser T, Napier H.G, Burri C, Lengeler C. Health system readiness and the implementation of rectal artesunate for severe malaria in sub-Saharan Africa: an analysis of real-world costs and constraints. Lancet Glob Health. 2023;11(2):e256-e264. DOI: 10.1016/S2214-109X(22)00507-1

Mäser P, Bernhard S, Brun R, Burri C, Gagneux S, Hetzel M.W, Kaiser M, Lengeler C, Pluschke G, Reus E, Rottmann M, Utzinger J, Warryn L, Wittlin S, Keiser J. Key contributions by the Swiss Tropical and Public Health Institute towards new and better drugs for tropical diseases. Chimia (Aarau). 2023;77(9):593-606. DOI: 10.2533/chimia.2023.593

Meier L, Antillón M, Burri C, Chitnis N, Endriss Y, Keiser J, Moore S, Müller P, Penny M, Voss T.S, Mäser P, Utzinger J. Repurposing know-how for drug development: case studies from the Swiss Tropical and Public Health Institute. Chimia (Aarau). 2023;77(9):582-592. DOI: 10.2533/chimia.2023.582

Menang O, Kümmerle A, Maigetter K, Burri C. Strategies and interventions to strengthen pharmacovigilance systems in low-income and middle-income countries: a scoping review. BMJ Open. 2023;13(9):e071079. DOI: 10.1136/bmjopen-2022-071079

Nébié E.I, Sawadogo H.N, van Eeuwijk P, Signorell A, Reus E, Utzinger J, Burri C. Opportunities and challenges for decentralised clinical trials in sub-Saharan Africa: a qualitative study. BMJ Open. 2023;13(9):e075903. DOI: 10.1136/bmjopen-2023-075903

Okitawutshu J, Tshefu A, Kalenga J.C, Delvento G, Burri C, Hetzel M.W, Lengeler C, Signorell A. Assessing caregivers' perceptions of treatment-seeking for suspected severe malaria in the Democratic Republic of the Congo. Malar J. 2023;22:308. DOI: 10.1186/s12936-023-04737-6

Signorell A, Awor P, Okitawutshu J, Tshefu A, Omoluabi E, Hetzel M.W, Athieno P, Kimera J, Tumukunde G, Angiro I, Kalenga J.C, Akano B.K, Ayodeji K, Okon C, Yusuf O, Delvento G, Lee T.T, Brunner N.C, Lambiris M.J, Okuma J, Cereghetti N, Buj V, Visser T, Napier H.G, Lengeler C, Burri C. Health worker compliance with severe malaria treatment guidelines in the context of implementing pre-referral rectal artesunate in the Democratic Republic of the Congo, Nigeria, and Uganda: an operational study. PLoS Med. 2023;20(2):e1004189. DOI: 10.1371/journal.pmed.1004189

van Zyl-Hermann D, Hammel T, Burri C, Chenal J, Fink G, Konou A.A, Nébié E.I, Osei Afriyie D, Pessoa Colombo V, Utzinger J, Tischler J. Examining African contributions to global health: reflections on knowledge circulation and innovation. Glob Public Health. 2023;18(1):2118343. DOI: 10.1080/17441692.2022.2118343

Awor P, Kimera J, Athieno P, Tumukunde G, Okitawutshu J, Tshefu A, Omoluabi E, Signorell A, Brunner N, Kalenga J.C, Akano B, Ayodeji K, Okon C, Yusuf O, Delvento G, Lee T, Burri C, Lengeler C, Hetzel M.W. Acceptability of pre-referral rectal artesunate for severe malaria in children under 5 years by health workers and caregivers in the Democratic Republic of the Congo, Nigeria and Uganda. Malar J. 2022;21:322. DOI: 10.1186/s12936-022-04348-7

Awor P, Kimera J, Brunner N.C, Athieno P, Tumukunde G, Angiro I, Signorell A, Delvento G, Lee T, Amutuhaire M, Opigo J, Kaggwa F.M, Kagwire F, Nakiganda J, Burri C, Lengeler C, Hetzel M.W. Care seeking and treatment of febrile children with and without danger signs of severe disease in northern Uganda: results from three household surveys (2018-2020). Am J Trop Med Hyg. 2022;107(4):934–938. DOI: 10.4269/ajtmh.21-1132

Bernhard S, Kaiser M, Burri C, Mäser P. Fexinidazole for human African trypanosomiasis, the fruit of a successful public-private partnership. Diseases. 2022;10(4):90. DOI: 10.3390/diseases10040090

Brunner N.C, Omoluabi E, Awor P, Okitawutshu J, Tshefu Kitoto A, Signorell A, Akano B, Ayodeji K, Okon C, Yusuf O, Athieno P, Kimera J, Tumukunde G, Angiro I, Kalenga J.C, Delvento G, Lee T.T, Lambiris M.J, Ross A, Cereghetti N, Visser T, Napier H.G, Buj V, Burri C, Lengeler C, Hetzel M.W. Prereferral rectal artesunate and referral completion among children with suspected severe malaria in the Democratic Republic of the Congo, Nigeria and Uganda. BMJ Glob Health. 2022;7(5):e008346. DOI: 10.1136/bmjgh-2021-008346

De Pretto-Lazarova A, Fuchs C, van Eeuwijk P, Burri C. Defining clinical trial quality from the perspective of resource-limited settings: a qualitative study based on interviews with investigators, sponsors, and monitors conducting clinical trials in sub-Saharan Africa. PLoS Negl Trop Dis. 2022;16(1):e0010121. DOI: 10.1371/journal.pntd.0010121

Hetzel M.W, Okitawutshu J, Tshefu A, Omoluabi E, Awor P, Signorell A, Brunner N.C, Kalenga J.C, Akano B.K, Ayodeji K, Okon C, Yusuf O, Athieno P, Kimera J, Tumukunde G, Angiro I, Delvento G, Lee T.T, Lambiris M.J, Kwiatkowski M, Cereghetti N, Visser T, Napier H.G, Cohen J.M, Buj V, Burri C, Lengeler C. Effectiveness of rectal artesunate as pre-referral treatment for severe malaria in children under 5 years of age: a multi-country observational study. BMC Med. 2022;20:343. DOI: 10.1186/s12916-022-02541-8

Kaboré J.M.T, Siribié M, Hien D, Soulama I, Barry N, Nombré Y, Dianda F, Baguiya A, Tiono A.B, Burri C, Tchouatieu A.M, Sirima S.B. Attitudes, practices, and determinants of community care-seeking behaviours for fever/malaria episodes in the context of the implementation of multiple first-line therapies for uncomplicated malaria in the health district of Kaya, Burkina Faso. Malar J. 2022;21:155. DOI: 10.1186/s12936-022-04180-z

Lengeler C, Burri C, Awor P, Athieno P, Kimera J, Tumukunde G, Angiro I, Tshefu A, Okitawutshu J, Kalenga J.-C, Omoluabi E, Akano B, Ayodeji K, Okon C, Yusuf O, Brunner N.C, Delvento G, Lee T, Lambiris M.J, Visser T, Napier H.G, Cohen J.M, Buj V, Signorell A, Hetzel Manuel W, Caramal Consortium. Community access to rectal artesunate for malaria (CARAMAL): a large-scale observational implementation study in the Democratic Republic of the Congo, Nigeria and Uganda. PLoS Glob Public Health. 2022;2(9):e0000464. DOI: 10.1371/journal.pgph.0000464

Ntamabyaliro N.Y, Burri C, Lula Y.N, Nzolo D.B, Engo A.B, Ngale M.A, Situakibanza H.N, Mukomena E.S, Mesia G.K, Mampunza S.M, Tona G.L. Determinants of patients' adherence to malaria treatment in the Democratic Republic of the Congo. Trop Med Infect Dis. 2022;7(7):138. DOI: 10.3390/tropicalmed7070138

Okitawutshu J, Signorell A, Kalenga J.C, Mukomena E, Delvento G, Burri C, Mwaluke F, Buj V, Sangare M, Luketa S, Brunner N, Lee T, Hetzel M, Lengeler C, Tshefu A. Key factors predicting suspected severe malaria case management and health outcomes: an operational study in the Democratic Republic of the Congo. Malar J. 2022;21:274. DOI: 10.1186/s12936-022-04296-2

Awor P, Khim N, Coppée R, Rondepierre L, Roesch C, Khean C, Kul C, Eam R, Lorn T, Athieno P, Kimera J, Clain J, Ringwald P, Signorell A, Lengeler C, Burri C, Ariey F, Hetzel M.W, Witkowski B. Clonal expansion of artemisinin-resistant Plasmodium falciparum in Uganda is associated with substandard treatment practices. Lancet. 2021(in press). DOI: 10.2139/ssrn.3974542

Burri C, Gerold J. Executive summary: external assessment of Unitaid’s human subject research management. Basel: Swiss TPH, 2021

Das A.M, Chitnis N, Burri C, Paris D.H, Patel S, Spencer S.E.F, Miaka E.M, Castaño M.S. Modelling the impact of fexinidazole use on human African trypanosomiasis (HAT) transmission in the Democratic Republic of the Congo. PLoS Negl Trop Dis. 2021;15(11):e0009992. DOI: 10.1371/journal.pntd.0009992

De Pretto-Lazarova A, Brancati-Badarau D.O, Burri C. Transparent reporting of recruitment and informed consent approaches in clinical trials recruiting children with minor parents in sub-Saharan Africa: a secondary analysis based on a systematic review. BMC Public Health. 2021;21:1473. DOI: 10.1186/s12889-021-11079-y

Kümmerle A, Schmid C, Bernhard S, Kande V, Mutombo W, Ilunga M, Lumpungu I, Mutanda S, Nganzobo P, Tete D.N, Kisala M, Burri C, Blesson S, Valverde Mordt O. Effectiveness of Nifurtimox Eflornithine Combination Therapy (NECT) in T. b. gambiense second stage sleeping sickness patients in the Democratic Republic of Congo: report from a field study. PLoS Negl Trop Dis. 2021;15(11):e0009903. DOI: 10.1371/journal.pntd.0009903

Kümmerle A, Sikalengo G, Vanobberghen F, Ndege R.C, Foe G, Schlaeppi C, Burri C, Battegay M, Paris D.H, Glass T.R, Weisser M, Marzolini C, Kiularco Study Group. Recognition and management of clinically significant drug-drug interactions between antiretrovirals and co-medications in a cohort of people living with HIV in rural Tanzania: a prospective questionnaire-based study. J Antimicrob Chemother. 2021;76(10):2681-2689. DOI: 10.1093/jac/dkab254

Lee T.T, Omoluabi E, Ayodeji K, Yusuf O, Okon C, Brunner N.C, Delvento G, Signorell A, Lambiris M, Kwiatkowski M, Burri C, Lengeler C, Emedo E, Cheshi F, Hetzel M.W. Treatment-seeking for children with suspected severe malaria attending community health workers and primary health centres in Adamawa State, Nigeria. medRxiv. 2021(in press). DOI: 10.1101/2021.12.01.21267130

Ntamabyaliro N.Y, Burri C, Lula Y.N, Ishoso D, Engo A.B, Ngale M.A, Liwono J.Y, Mukomena E.S, Mesia G.K, Mampunza S.M, Tona G.L. Knowledge of antimalarials and health seeking behaviour of households in case of suspected malaria in Democratic Republic of the Congo. Trop Med Infect Dis. 2021;6(3):157. DOI: 10.3390/tropicalmed6030157

Signorell A, Saric J, Appenzeller-Herzog C, Ewald H, Burri C, Goetz M, Gerold J. Methodological approaches for conducting follow-up research with clinical trial participants: a scoping review and expert interviews. Trials. 2021;22:961. DOI: 10.1186/s13063-021-05866-6

Blum A, Mudji J, Grize L, Burri C, Zellweger M.J, Blum J. Sleeping hearts: 12 years after a follow up study on cardiac findings due to sleeping sickness. One Health. 2020;11:100182. DOI: 10.1016/j.onehlt.2020.100182

Burri C. Sleeping sickness at the crossroads. Trop Med Infect Dis. 2020;5(2):57. DOI: 10.3390/tropicalmed5020057

Burri C, ed. Human African trypanosomiasis (sleeping sickness): the road to elimination revisited - achievements and remaining challenges. Basel: MDPI, 2020. Printed edition of the special issue published in . DOI: 10.3390/books978-3-03928-964-6

De Pretto-Lazarova A, Brancati-Badarau D.O, Burri C. Informed consent approaches for clinical trial participation of infants with minor parents in sub-Saharan Africa: a systematic review. PLoS One. 2020;15(8):e0237088. DOI: 10.1371/journal.pone.0237088

Dickie E.A, Giordani F, Gould M.K, Mäser P, Burri C, Mottram J.C, Rao S.P.S, Barrett M.P. New drugs for human African trypanosomiasis: a twenty first century success story. Trop Med Infect Dis. 2020;5:29. DOI: 10.3390/tropicalmed5010029

Mudji J, Blum A, Grize L, Wampfler R, Ruf M.T, Cnops L, Nickel B, Burri C, Blum J. Gambiense human African trypanosomiasis sequelae after treatment: a follow-up study 12 years after treatment. Trop Med Infect Dis. 2020;5(1):10. DOI: 10.3390/tropicalmed5010010

Seixas J, Atouguia J, Josenando T, Vatunga G, Bilenge C.M.M, Lutumba P, Burri C. Clinical study on the melarsoprol-related encephalopathic syndrome: risk factors and HLA association. Trop Med Infect Dis. 2020;5(1):5. DOI: 10.3390/tropicalmed5010005

Mudji J, Benhamou J, Mwamba-Miaka E, Burri C, Blum J. The flipside of eradicating a disease; human African trypanosomiasis in a woman in rural Democratic Republic of Congo: a case report. Trop Med Infect Dis. 2019;4(4):142. DOI: 10.3390/tropicalmed4040142

Nzolo D, Kümmerle A, Lula Y, Ntamabyaliro N, Engo A, Mvete B, Liwono J, Lusakibanza M, Mesia G, Burri C, Mampunza S, Tona G. Development of a pharmacovigilance system in a resource-limited country: the experience of the Democratic Republic of Congo. Ther Adv Drug Saf. 2019;10:2042098619864853. DOI: 10.1177/2042098619864853

Kümmerle A, Akakpo S, Liwono J, Duparc S, Burri C, Stergachis A. Drug utilization and drug-drug interaction studies in the field: examples of South-North collaboration projects. Drug Safety, 2018;41(11):1120-1121

Lengeler C, Hetzel M, Signorell A, Awor P, Tshefu A, Okitawutshu J, Omoluabi E, Nepomnyashchiy L, Fast J, Ramachandra S, Goldstein R, Buj V, Burri C. Introducing rectal artesunate in community settings and evaluating its impact. 7th MIM Pan African Malaria Conference. Dakar, Senegal, 2018

Ntamabyaliro N.Y, Burri C, Nzolo D.B, Engo A.B, Lula Y.N, Mampunza S.M, Nsibu C.N, Mesia G.K, Kayembe J.N, Likwela J.L, Kintaudi L.M, Tona G.L. Drug use in the management of uncomplicated malaria in public health facilities in the Democratic Republic of the Congo. Malar J. 2018;17:189. DOI: 10.1186/s12936-018-2332-3

Signorell A, Hetzel M, Awor P, Tshefu A, Okitawutshu J, Omoluabi E, Nepomnyashchiy L, Burri C, Lengeler C. CARAMAL: addressing the remaining burden of malaria deaths by optimizing the use of rectla artesunate. 7th MIM Pan African Malaria Conference. Dakar, Senegal, 2018

Simon A, Marzolini C, Vanobbergen F, Burri C, Kümmerle A. Reporting of qt interval prolongation and torsade de pointe for HIV-antiretrovirals in vigibase: focus on potential drug-drug interactions. Drug Safety, 2018;41(11):1178-1179

Burri C, Blum J. Human African trypanosomiasis. In: Cohen Jonathan,Powderly William G,Opal Steven M, eds. Infectious Diseases. 2, 966-970;1761-1762: Elsevier, 2017

Kümmerle A, Mäder M, Sartori D, Lazarova A, Urich M, Dodoo A, Olsson S, Burri C. Contribution of adverse events reporting of HIV antiretrovirals to VigiBase: Comparison between sub-Saharan Africa and the rest of the world. Drug Safety. 2017;40(10):987-988

Kümmerle A, Sartori D, Maeder M, Lazarova A, Urich M, Dodoo A, Olsson S, Burri C. Spontaneous reporting characteristics of HIV antiretrovirals in vigibase: disproportionate analysis between sub-Saharan Africa and the rest of the world. Drug Saf, 2017;40(10):988-989

Vischer N, Pfeiffer C, Kealy J, Burri C. Increasing protocol suitability for clinical trials in sub-Saharan Africa: a mixed methods study. Glob Health Res Policy. 2017;2:11. DOI: 10.1186/s41256-017-0031-1

Vischer N, Pfeiffer C, Limacher M, Burri C. "You can save time if..."-a qualitative study on internal factors slowing down clinical trials in sub-Saharan Africa. PLoS One. 2017;12(3):e0173796. DOI: 10.1371/journal.pone.0173796

Burri C, Yeramian P.D, Allen J.L, Merolle A, Serge K.K, Mpanya A, Lutumba P, Mesu V.K, Bilenge C.M, Lubaki J.P, Mpoto A.M, Thompson M, Munungu B.F, Manuel F, Josenando T, Bernhard S.C, Olson C.A, Blum J, Tidwell R.R, Pohlig G. Efficacy, safety, and dose of pafuramidine, a new oral drug for treatment of first stage sleeping sickness, in a phase 2a clinical study and phase 2b randomized clinical studies. PLoS Negl Trop Dis. 2016;10(2):e0004362. DOI: 10.1371/journal.pntd.0004362

Ntuku H.M, Ferrari G, Burri C, Tshefu A.K, Kalemwa D.M, Lengeler C. Feasibility and acceptability of injectable artesunate for the treatment of severe malaria in the Democratic Republic of Congo. Malar J. 2016;15:18. DOI: 10.1186/s12936-015-1072-x

Pohlig G, Bernhard S.C, Blum J, Burri C, Mpanya A, Lubaki J.P, Mpoto A.M, Munungu B.F, N'tombe P.M, Deo G.K, Mutantu P.N, Kuikumbi F.M, Mintwo A.F, Munungi A.K, Dala A, Macharia S, Bilenge C.M, Mesu V.K, Franco J.R, Dituvanga N.D, Tidwell R.R, Olson C.A. Efficacy and safety of pafuramidine versus pentamidine maleate for treatment of first stage sleeping sickness in a randomized, comparator-controlled, international phase 3 clinical trial. PLoS Negl Trop Dis. 2016;10(2):e0004363. DOI: 10.1371/journal.pntd.0004363

Vischer N, Pfeiffer C, Joller A, Klingmann I, Ka A, Kpormegbe S.K, Burri C. The good clinical practice guideline and its interpretation - perceptions of clinical trial teams in sub-Saharan Africa. Trop Med Int Health. 2016;21(8):1040-1048. DOI: 10.1111/tmi.12734

Ferrari G, Ntuku H.M, Burri C, Kitoto A.T, Duparc S, Hugo P, Mitembo D.K, Ross A, Ngwala P.L, Luwawu J.N, Musafiri P.N, Ngoie S.E, Lengeler C. An operational comparative study of quinine and artesunate for the treatment of severe malaria in hospitals and health centres in the Democratic Republic of Congo: the MATIAS study. Malar J. 2015;14:226. DOI: 10.1186/s12936-015-0732-1

Ferrari G, Ntuku H.M, Burri C, Kitoto A.T, Duparc S, Hugo P, Mitembo D.K, Ross A, Ngwala P.L, Luwawu N, Musafiri P.N, Ngoie S.E, Lengeler C. An operational comparative study of quinine and artesunate for the treatment of severe malaria in hospitals and health centres in The Democratic Republic of Congo: the MATIAS study. Trop Med Int Health, 2015;20(Suppl. 1):91. Abstracts of the 9th European Congress on Tropical Medicine and International Health, 6-10 September 2015, Basel, Switzerland

Gajewski S, Burri C. Clinical research data management: solutions for low-resource settings. Trop Med Int Health, 2015;20(Suppl. 1):432-433

Signorell A, Torrente M, Scherrer B, Mordt O.V, Strub-Wourgaft N, Tarral A, Burri C. Safety and efficacy of fexinidazole against rhodesiense human African trypanosomiasis: approach to conducting a clinical trial for a very rare, neglected disease. Trop Med Int Health, 2015;20(Suppl. 1):337. Abstracts of the 9th European Congress on Tropical Medicine and International Health, 6-10 September 2015, Basel, Switzerland

Vischer N, Pfeiffer C, Burri C. Improving efficiency and quality in clinical trials in sub-Saharan Africa. Trop Med Int Health, 2015;20(Suppl. 1):125. Abstracts of the 9th European Congress on Tropical Medicine and International Health, 6-10 September 2015, Basel, Switzerland

Burri C, Chappuis F, Brun R. Human African trypanosomiasis. In: Farrar J,Hotez P.J,Junghanss T,Kang G,Lalloo D,White N.J, eds. Manson's Tropical Diseases, 606-621. [Edinburgh]: Saunders, 2014

Burri C, Ferrari G, Ntuku H.M, Kitoto A.T, Duparc S, Hugo P, Mitembo D.K, Lengeler C. Delayed anemia after treatment with injectable artesunate in the democratic republic of the Congo: a manageable issue. Am J Trop Med Hyg. 2014;91(4):821-823. DOI: 10.4269/ajtmh.14-0149

Burri C. Antiprotozoals for human African trypanosomiasis: the heart of darkness at dawn [Commentary]. Clin Invest. 2014;4(1):13-18. DOI: 10.4155/CLI.13.116

Williams J.R, Sprumont D, Hirtle M, Adebamowo C, Braunschweiger P, Bull S, Burri C, Czarkowski M, Fan C.T, Franck C, Gefenas E, Geissbuhler A, Klingmann I, Kouyate B, Kraehenbhul J.P, Kruger M, Moodley K, Ntoumi F, Nyirenda T, Pym A, Silverman H, Tenorio S. Consensus standards for introductory e-learning courses in human participants research ethics. J Med Ethics. 2014;40(6):426-428. DOI: 10.1136/medethics-2013-101572

Burri C, Ferrari G, Ntuku H.M, Mitembo D.K, Ngwala P.L, Luwawu J.J.N, Musafiri P.N, Ngoie S.E, Hugo P, Kitoto A.T, Lengeler C. Treatment of severe malaria: an operational comparison between quinine and artesunate for the treatment of severe malaria in seven health facilities in the democratic republic of the Congo - "Matias". Am J Trop Med Hyg, 2013;89(5 Suppl.):199

Burri C. An alternative form of melarsoprol in sleeping sickness: is an old drug always the best basis for a new one? [Letter]. Trends Parasitol. 2012;28(9):354-355. DOI: 10.1016/j.pt.2012.06.002

Küpfer I, Schmid C, Allan M, Edielu A, Haary E.P, Kakembo A, Kibona S, Blum J, Burri C. Safety and efficacy of the 10-day melarsoprol schedule for the treatment of second stage rhodesiense sleeping sickness. PLoS Negl Trop Dis. 2012;6(8):e1695. DOI: 10.1371/journal.pntd.0001695

Fenner L, Gagneux S, Kabuya G, Stucki D, Kabuayi J.P, Borrell S, Frei R, Burri C, Kalemwa D, Egger M, Okiata J.P. Mycobacterium tuberculosis genetic diversity and drug resistance conferring mutations in the Democratic Republic of the Congo. East Afr Med J. 2011;88(12):409-415

Kümmerle A, Dodoo A.N.O, Olsson S, Van Erps J, Burri C, Lalvani P.S. Assessment of global reporting of adverse drug reactions for anti-malarials, including artemisinin-based combination therapy, to the WHO Programme for International Drug Monitoring. Malar J. 2011;10:57. DOI: 10.1186/1475-2875-10-57

Küpfer I, Hhary E.P, Allan M, Edielu A, Burri C, Blum J.A. Clinical presentation of T.b. rhodesiense sleeping sickness in second stage patients from Tanzania and Uganda. PLoS Negl Trop Dis. 2011;5(3):e968. DOI: 10.1371/journal.pntd.0000968

Probst-Hensch N, Tanner M, Kessler C, Burri C, Künzli N. Prevention--a cost-effective way to fight the non-communicable disease epidemic: an academic perspective of the United Nations High-level NCD Meeting. Swiss Med Wkly. 2011;141:w13266. DOI: 10.4414/smw.2011.13266

Schweizerisches Tropen- und Public Health-Institut. Eine vergessene Seuche: Erforschung und Bekämpfung der afrikanischen Schlafkrankheit am Swiss TPH. Basel: Schweizerisches Tropen- und Public Health-Institut, 2011

Swiss Tropical and Public Health Institute. A forgotten epidemic: study and prevention of African sleeping sickness at the Swiss TPH. Basel: Swiss Tropical and Public Health Institute, 2011

Brun R, Blum J, Chappuis F, Burri C. Human African trypanosomiasis. Lancet. 2010;375(9709):148-159. DOI: 10.1016/S0140-6736(09)60829-1

Burri C. Chemotherapy against human African trypanosomiasis: is there a road to success?. Parasitology. 2010;137(14):1987-1994. DOI: 10.1017/S0031182010001137

Matovu E, Küpfer I, Boobo A, Kibona S, Burri C. Comparative detection of trypanosomal DNA by loop mediated isotherma amplification and PCR from FTA cards spotted with patient blood. J Clin Microbiol. 2010;48(6):2087-2090. DOI: 10.1128/JCM.00101-10

Paine M.F, Wang M.Z, Generaux C.N, Boykin D.W, Wilson W.D, de Koning H.P, Olson C.A, Pohlig G, Burri C, Brun R, Murilla G.A, Thuita J.K, Barrett M.P, Tidwell R.R. Diamidines for human African trypanosomiasis. Curr Opin Investig Drugs. 2010;11(8):876-883

Blum J, Schmid C, Burri C, Hatz C, Olson C, Fungula B, Kazumba L, Mangoni P, Mbo F, Deo K, Mpanya A, Dala A, Franco J.R, Pohlig G, Zellweger M.J. Cardiac alterations in human African trypanosomiasis (T.b. gambiense) with respect to the disease stage and antiparasitic treatment. PLoS Negl Trop Dis. 2009;3(2):e383. DOI: 10.1371/journal.pntd.0000383